ClinicalTrials.gg
CompletedNCT02544451Updated May 24, 2021Results posted

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

A Phase 3 interventional study of LUM/IVA and LUM/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 61 sites in 9 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2021-05-24.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
246
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
5th of 20
246 · median 66
Started
2015
with 2 others
Phase 3
10 of 20
none open now
Registered
14th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 5th largest by enrollment, is one of 3 that started in 2015, is one of 10 in phase 3, and was the 14th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233). Study 110 is designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects entering the Treatment Cohort must meet both of the following criteria:

  • Completed study visits up to Week 24 of Study 109 or Week 26 of Study 011B and did not permanently discontinue treatment
  • Willing to remain on a stable CF medication through the Safety Follow-up Visit.

Subjects entering the Observational Cohort must meet 1 of the following criteria:

  • Completed 24 weeks of study drug treatment in Study 109 or completed 24 weeks of study drug treatment and the Week 26 Safety Follow up in Study 011B.
  • Received at least 4 weeks of study drug and completed visits up to Week 24 of Study 109 or Week 26 of Study 011B.

Exclusion criteria

Exclusion Criteria (Treatment Cohort Only):

  • History of any comorbidity or laboratory abnormality that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject (e.g., cirrhosis with portal hypertension).
  • Pregnant and nursing females.
  • Sexually active subjects of who are not willing to follow the requirements.
  • History of drug intolerance in the prior study that would pose an additional risk to the subject in the opinion of investigator
  • History of poor compliance with study drug and/or procedure in the previous study as deemed by the investigator.
  • Participation in an drug trial (including studies investigating lumacaftor and/or ivacaftor).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
246 participants (actual)

Study arms

  • Experimental
    Treatment Period 1: LUM/IVA to LUM/IVA

    Drug: LUM/IVA

  • Experimental
    Treatment Period 1: Placebo (PBO) to LUM/IVA

    Drug: LUM/IVA

  • No intervention
    Treatment Period 1: Observational Cohort
  • Experimental
    Treatment Period 2: LUM/IVA

    Drug: LUM/IVA

Interventions

  • DrugLUM/IVA

    Drug pages: Lumacaftor · Ivacaftor

    Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age). LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older).

    Also known as: VX-809/VX-770, lumacaftor/ivacaftor

  • DrugLUM/IVA

    Drug pages: Lumacaftor · Ivacaftor

    LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).

    Also known as: VX-809/VX-770, lumacaftor/ivacaftor

06

What researchers measure

Primary outcomes

  1. Treatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 100

Secondary outcomes

  1. Absolute Change in Lung Clearance Index (LCI) 2.5

    LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

    Time frame: From Parent Study Baseline at Week 96

  2. Absolute Change in Sweat Chloride

    Sweat samples were collected using an approved collection device.

    Time frame: From Parent Study Baseline at Week 96

  3. Absolute Change in Body Mass Index (BMI)

    BMI was defined as weight in kilograms divided by height in square meter (m\^2).

    Time frame: From Parent Study Baseline at Week 96

  4. Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Parent Study Baseline at Week 96

  5. Observational Cohort: Safety as Assessed by Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 100

  6. Absolute Change in LCI 5.0

    LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.

    Time frame: From Parent Study Baseline at Week 96

  7. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Parent Study Baseline at Week 96

  8. Relative Change in ppFEV1

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Parent Study Baseline at Week 96

  9. Absolute Change in BMI-for-age Z-score

    BMI was defined as weight in kilograms divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

    Time frame: From Parent Study Baseline at Week 96

  10. Absolute Change in Weight

    Time frame: From Parent Study Baseline at Week 96

  11. Absolute Change in Weight-for-age Z-score

    z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

    Time frame: From Parent Study Baseline at Week 96

  12. Absolute Change in Height

    Time frame: From Parent Study Baseline at Week 96

  13. Absolute Change in Height-for-age Z-score

    z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

    Time frame: From Parent Study Baseline at Week 96

  14. Absolute Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Domain Score

    The TSQM measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed in the total domain score, which ranges from 0 to 100, where higher scores indicate greater satisfaction.

    Time frame: From Parent Study Baseline at Week 96

  15. Time-to-first Pulmonary Exacerbation

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: From Parent Study Baseline through Week 96

  16. Percentage of Participants Having At Least 1 Pulmonary Exacerbation Event

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: From Parent Study Baseline through Week 96

  17. Number of Pulmonary Exacerbation Events Per Patient-year

    Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

    Time frame: From Parent Study Baseline through Week 96

  18. Rate of Change in LCI 2.5

    Rate of change analysis evaluates the change in LCI 2.5 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.

    Time frame: Day 15 after first dose of LUM/IVA through Week 96

  19. Rate of Change in LCI 5.0

    Rate of change analysis evaluates the change in LCI 5.0 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.

    Time frame: Day 15 after first dose of LUM/IVA through Week 96

  20. Rate of Change in ppFEV1

    Rate of change analysis evaluates the change in ppFEV1 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.

    Time frame: Day 15 after first dose of LUM/IVA through Week 96

  21. Treatment Period 2: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 168

07

Results

Posted Oct 29, 2019

Participant flow

This study consists of 2 Treatment Periods: Treatment Period 1 and Treatment Period 2. Treatment Period 1 had Treatment Cohorts and an Observational Cohort.

Treatment Period 1 (96 Weeks)
Participant flow — Treatment Period 1 (96 Weeks)
MilestoneTreatment Period 1: LUM/IVA to LUM/IVATreatment Period 1: PBO to LUM/IVATreatment Period 1: Observational CohortTreatment Period 2: LUM/IVA
Started1439660
Completed1298450
Not completed141210
Withdrew: Adverse event1600
Withdrew: Withdrawal of consent (not due to ae)3210
Withdrew: Lost to follow-up2000
Withdrew: Physician decision4000
Withdrew: Other4400
Treatment Period 2 (168 Weeks)
Participant flow — Treatment Period 2 (168 Weeks)
MilestoneTreatment Period 1: LUM/IVA to LUM/IVATreatment Period 1: PBO to LUM/IVATreatment Period 1: Observational CohortTreatment Period 2: LUM/IVA
Started00010
Completed0000
Not completed00010
Withdrew: Commercial drug is available for subject00010

Outcome measures

PrimaryTreatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 100
Reported as:
Number · participants
Treatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsLUM/IVA to LUM/IVAPBO to LUM/IVA
Participants with any AEs14294
Participants with SAEs4329
SecondaryAbsolute Change in Lung Clearance Index (LCI) 2.5

LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · lung clearance index
Absolute Change in Lung Clearance Index (LCI) 2.5
lung clearance indexLUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in Lung Clearance Index (LCI) 2.5-0.85 (-1.25 to -0.45)-0.86 (-1.33 to -0.38)
SecondaryAbsolute Change in Sweat Chloride

Sweat samples were collected using an approved collection device.

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride
millimole per liter (mmol/L)LUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in Sweat Chloride-22.9 (-25.5 to -20.3)-22.8 (-26.3 to -19.3)
SecondaryAbsolute Change in Body Mass Index (BMI)

BMI was defined as weight in kilograms divided by height in square meter (m\^2).

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · kg/m^2
Absolute Change in Body Mass Index (BMI)
kg/m^2LUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in Body Mass Index (BMI)1.78 (1.56 to 1.99)2.04 (1.77 to 2.31)
SecondaryAbsolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · units on a scale
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
units on a scaleLUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score7.4 (4.8 to 10.0)6.6 (3.1 to 10.0)
SecondaryObservational Cohort: Safety as Assessed by Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 100
Reported as:
Number · participants
Observational Cohort: Safety as Assessed by Serious Adverse Events (SAEs)
participantsObservational Cohort
Observational Cohort: Safety as Assessed by Serious Adverse Events (SAEs)1
SecondaryAbsolute Change in LCI 5.0

LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · lung clearance index
Absolute Change in LCI 5.0
lung clearance indexLUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in LCI 5.0-0.21 (-0.36 to -0.06)-0.31 (-0.49 to -0.13)
SecondaryAbsolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · percent predicted of FEV1
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percent predicted of FEV1LUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)3.1 (1.0 to 5.1)0.0 (-2.7 to 2.7)
SecondaryRelative Change in ppFEV1

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · percent change
Relative Change in ppFEV1
percent changeLUM/IVA to LUM/IVAPBO to LUM/IVA
Relative Change in ppFEV14.9 (2.2 to 7.5)0.5 (-2.9 to 4.0)
SecondaryAbsolute Change in BMI-for-age Z-score

BMI was defined as weight in kilograms divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · z-score
Absolute Change in BMI-for-age Z-score
z-scoreLUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in BMI-for-age Z-score0.17 (0.08 to 0.26)0.31 (0.19 to 0.42)
SecondaryAbsolute Change in Weight
Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · kg
Absolute Change in Weight
kgLUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in Weight10.3 (9.6 to 11.0)11.0 (10.1 to 11.8)
SecondaryAbsolute Change in Weight-for-age Z-score

z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · z-score
Absolute Change in Weight-for-age Z-score
z-scoreLUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in Weight-for-age Z-score0.12 (0.04 to 0.20)0.24 (0.14 to 0.34)
SecondaryAbsolute Change in Height
Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · centimeter (cm)
Absolute Change in Height
centimeter (cm)LUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in Height13.4 (12.9 to 14.0)13.5 (12.8 to 14.1)
SecondaryAbsolute Change in Height-for-age Z-score

z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · z-score
Absolute Change in Height-for-age Z-score
z-scoreLUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in Height-for-age Z-score-0.01 (-0.08 to 0.07)0.02 (-0.07 to 0.11)
SecondaryAbsolute Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Domain Score

The TSQM measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed in the total domain score, which ranges from 0 to 100, where higher scores indicate greater satisfaction.

Time frame:
From Parent Study Baseline at Week 96
Reported as:
Least squares mean · units on a scale
Absolute Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Domain Score
units on a scaleLUM/IVA to LUM/IVAPBO to LUM/IVA
Absolute Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Domain Score5.1 (1.7 to 8.4)3.9 (-0.6 to 8.5)
SecondaryTime-to-first Pulmonary Exacerbation

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
From Parent Study Baseline through Week 96
Reported as:
Median · days
Time-to-first Pulmonary Exacerbation
daysLUM/IVA to LUM/IVAPBO to LUM/IVA
Time-to-first Pulmonary Exacerbation720.00 (278.00 to NA)NA (513.00 to NA)
SecondaryPercentage of Participants Having At Least 1 Pulmonary Exacerbation Event

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
From Parent Study Baseline through Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Having At Least 1 Pulmonary Exacerbation Event
percentage of participantsLUM/IVA to LUM/IVAPBO to LUM/IVA
Percentage of Participants Having At Least 1 Pulmonary Exacerbation Event49.532.3
SecondaryNumber of Pulmonary Exacerbation Events Per Patient-year

Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.

Time frame:
From Parent Study Baseline through Week 96
Reported as:
Number · events per patient-year
Number of Pulmonary Exacerbation Events Per Patient-year
events per patient-yearLUM/IVA to LUM/IVAPBO to LUM/IVA
Number of Pulmonary Exacerbation Events Per Patient-year0.45 (0.33 to 0.61)0.30 (0.21 to 0.43)
SecondaryRate of Change in LCI 2.5

Rate of change analysis evaluates the change in LCI 2.5 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.

Time frame:
Day 15 after first dose of LUM/IVA through Week 96
Reported as:
Number · slope
Rate of Change in LCI 2.5
slopeLUM/IVA Overall
Rate of Change in LCI 2.5-0.01 (-0.12 to 0.09)
SecondaryRate of Change in LCI 5.0

Rate of change analysis evaluates the change in LCI 5.0 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.

Time frame:
Day 15 after first dose of LUM/IVA through Week 96
Reported as:
Number · slope
Rate of Change in LCI 5.0
slopeLUM/IVA Overall
Rate of Change in LCI 5.00.00 (-0.04 to 0.04)
SecondaryRate of Change in ppFEV1

Rate of change analysis evaluates the change in ppFEV1 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.

Time frame:
Day 15 after first dose of LUM/IVA through Week 96
Reported as:
Number · slope
Rate of Change in ppFEV1
slopeLUM/IVA Overall
Rate of Change in ppFEV10.58 (0.02 to 1.14)
SecondaryTreatment Period 2: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 168
Reported as:
Number · participants
Treatment Period 2: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsTreatment Period 2: LUM/IVA
Participants with any AEs9
Participants with SAEs0

Adverse events

Collected over Treatment Period 1: Day 1 up to Week 100, Treatment Period 2: Day 1 up to Week 168. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period 1: LUM/IVA to LUM/IVA0/143 (0%)43/143 (30.1%)141/143 (98.6%)
Treatment Period 1: PBO to LUM/IVA0/96 (0%)29/96 (30.2%)93/96 (96.9%)
Treatment Period 1: Observational Cohort0/6 (0%)1/6 (16.7%)—
Treatment Period 2: LUM/IVA0/10 (0%)0/10 (0%)9/10 (90%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventTreatment Period 1: LUM/IVA to LUM/IVATreatment Period 1: PBO to LUM/IVATreatment Period 1: Observational CohortTreatment Period 2: LUM/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations34/14315/961/60/10
ConstipationGastrointestinal disorders4/1430/960/60/10
Pulmonary function test decreasedInvestigations2/1432/960/60/10
Alanine aminotransferase increasedInvestigations0/1432/960/60/10
Aspartate aminotransferase increasedInvestigations0/1432/960/60/10
Bronchopulmonary aspergillosis allergicInfections and infestations2/1430/960/60/10
PneumoniaInfections and infestations1/1431/960/60/10
AppendicitisInfections and infestations0/1431/960/60/10
Gastroenteritis viralInfections and infestations0/1431/960/60/10
Viral upper respiratory tract infectionInfections and infestations0/1431/960/60/10
Most frequent other events
Showing 10 of 70
Most frequent other events
EventTreatment Period 1: LUM/IVA to LUM/IVATreatment Period 1: PBO to LUM/IVATreatment Period 1: Observational CohortTreatment Period 2: LUM/IVA
CoughRespiratory, thoracic and mediastinal disorders91/14364/96—2/10
RhinitisInfections and infestations9/1437/96—6/10
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations59/14334/96—4/10
PyrexiaGeneral disorders45/14327/96—1/10
NasopharyngitisInfections and infestations21/14316/96—3/10
HeadacheNervous system disorders29/14326/96—1/10
Upper respiratory tract infectionInfections and infestations36/14313/96—0/10
Nasal congestionRespiratory, thoracic and mediastinal disorders34/14321/96—0/10
Oropharyngeal painRespiratory, thoracic and mediastinal disorders32/14318/96—0/10
Alanine aminotransferase increasedInvestigations22/14321/96—0/10

Baseline characteristics

Treatment Cohort: All participants dosed in the parent studies and dosed in the current study. Observational Cohort: All participants enrolled in the observational cohort of the current study.

Age, Customized
Age, Customized(Participants)LUM/IVA to LUM/IVAPBO to LUM/IVAObservational CohortTotal
Less than 9 Years58385101
Greater than or equal to 9 years85581144
Sex: Female, Male
Sex: Female, Male(Participants)LUM/IVA to LUM/IVAPBO to LUM/IVAObservational CohortTotal
Female83562141
Male60404104
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LUM/IVA to LUM/IVAPBO to LUM/IVAObservational CohortTotal
Hispanic or Latino2204
Not Hispanic or Latino139936238
Unknown or Not Reported2103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LUM/IVA to LUM/IVAPBO to LUM/IVAObservational CohortTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White140926238
More than one race0000
Unknown or Not Reported3306
08

Study locations

61 sites
  • Birmingham, Alabama, United States
  • Tucson, Arizona, United States
  • Long Beach, California, United States
  • Palo Alto, California, United States
  • Aurora, Colorado, United States
  • Wilmington, Delaware, United States
  • Jacksonville, Florida, United States
  • Orlando, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa, United States
  • Boston, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Lebanon, New Hampshire, United States
  • Buffalo, New York, United States
  • Syracuse, New York, United States
  • Chapel Hill, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Dayton, Ohio, United States
  • Portland, Oregon, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Austin, Texas, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Colchester, Vermont, United States
  • Charlottesville, Virginia, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Madison, Wisconsin, United States
  • Milwaukee, Wisconsin, United States
  • Parkville, Victoria, Australia
  • Herston, Australia
  • New Lambton Heights, Australia
  • Subiaco, Australia
  • Westmead, Australia
  • Brussels, Belgium
  • Leuven, Belgium
  • Vancouver, British Columbia, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Copenhagen, Denmark
  • Bron, Cedex, France
  • Bordeaux Cedex, France
  • Paris Cedex 15, France
  • Paris, France
  • Berlin, Germany
  • Giessen, Germany
  • Hanover, Germany
  • Koeln, Germany
  • Stockholm, Sweden
  • Leeds, West Yorkshire, United Kingdom
  • Belfast, United Kingdom
  • Edinburgh, United Kingdom
  • London, United Kingdom
09

References and documents

Publications

  • Chilvers MA, Davies JC, Milla C, Tian S, Han Z, Cornell AG, Owen CA, Ratjen F. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Lancet Respir Med. 2021 Jul;9(7):721-732. doi: 10.1016/S2213-2600(20)30517-8. Epub 2021 Jan 28. Erratum In: Lancet Respir Med. 2021 Apr;9(4):e38. doi: 10.1016/S2213-2600(21)00093-X. PubMed 33516285 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Aug 2018, 36 months.

Results were first posted in Oct 2019, 1 year 2 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 36 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2015
First posted
Sep 9, 2015
StartActual
Aug 2015
Primary completionActual
Aug 2018
CompletionActual
Apr 2020
Results first posted
Oct 29, 2019
Last update
May 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02544451
Responsible party
Sponsor
First posted
Sep 9, 2015
Start date
Aug 2015
Primary completion
Aug 2018
Completion
Apr 2020
Results posted
Oct 29, 2019
Last update
May 24, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lumacaftor · Ivacaftor

Start the discussion